HOME >> BIOLOGY >> NEWS
Data show investigational antibiotic safe, effective in preventing travelers diarrhea

New Orleans, LA — New data suggest the investigational drug rifaximin, a non-absorbed (less than .5%) antibiotic with few side effects and low potential for resistance, is effective in preventing travelers' diarrhea, an illness that affects up to 60 percent of international travelers. Until now, antimicrobial prophylaxis, while effective, has been discouraged because of side effects and the encouragement of resistance. The study results, presented Sunday, May 16 at the 2004 Digestive Disease Week (DDW) annual meeting by lead investigator, Herbert L. DuPont, M.D., Chief of the Internal Medicine Service at St. Luke's Episcopal Hospital in Houston, showed that, over two weeks, 85 percent of the rifaximin-treated subjects remained free of diarrhea, compared with 49 percent of the placebo-treated subjects.

Dr. DuPont is also Director, Center for Infectious Diseases, University of Texas, Houston School of Public Health and Vice-Chairman, Department of Medicine at Baylor College of Medicine.

Travelers' diarrhea threatens up to 50 million persons going to Mexico and Latin America, Africa and southern Asia each year. The illness can render travelers bed ridden for a full day or more, and considerably decrease their energy for up to a week or longer. In addition, a bout of travelers' diarrhea can also cause chronic diarrhea and long-lasting irritable bowel syndrome in some people. The antibiotic, rifaximin, with the projected brand name of Xifaxan, is currently under review by the U.S. Food and Drug Administration. It has previously been shown by researchers to be a safe and effective form of therapy for treatment of travelers' diarrhea in clinical studies conducted in Mexico, Peru, India and Kenya and has been prescribed internationally since 1987 and is currently approved in 17 countries worldwide.

"This is potentially one of the most important advances over the past 50 years toward reducing the occurrence of illness of travelers to
'"/>


16-May-2004


Page: 1 2 3

Related biology news :

1. Hemophilia therapy update: New information on investigational Factor VIII therapy development
2. New research on investigational Alzheimers disease treatment suggests significant improvement of symptoms
3. Anthrax enzyme images reveal secrets of antibiotic resistance, suggest new drug design
4. Smart antibiotics may result from UCLA research
5. K-State researcher working to improve alternatives to equine antibiotics
6. Bacterial protein recycling factor possible key to new class of antibiotics
7. Bacteria spill their guts to aid researchers in quest for new antibiotics
8. Molecule that blocks key bacterial enzyme may lead to new antibiotics
9. Does antibiotic use contribute to allergies?
10. Tigecycline - Candidate antibiotic produces 74 percent cure rate in cSSSI patients
11. Tigecycline - antibiotic evaluated in surveillance trial

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... , Dec. 5, 2016  The Office of ... published "Can CT Scans Enhance or Replace Medico ... potential of supporting or replacing forensic autopsies with ... scan. In response to recommendations made ... exploring using CT scans as a potential component ...
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a ... point-of-care products for the objective detection of concussion and ... company has successfully completed a meeting with the U.S. ... Tbit™ blood test Pre-Submission Package. During the meeting company ... system as a precursor to commencement of a planned ...
(Date:11/22/2016)... 2016 According to the new market research report ... Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), ... market is expected to grow from USD 10.74 Billion in 2015 to ... 2016 and 2022. Continue Reading ... ...
Breaking Biology News(10 mins):
(Date:12/9/2016)... MA (PRWEB) , ... December 09, 2016 , ... Aditya ... that in addition to Australia, Europe, and the United States, Axiomed is now gaining ... assure interest in this technology." , Mr. Humad went on to say that, “We ...
(Date:12/9/2016)... -- China Cord Blood Corporation (NYSE: CO ) ... provider of cord blood collection, laboratory testing, hematopoietic stem cell ... of its 2016 Annual General Meeting, which was held on ... . At the Annual General Meeting, ... Huazhen LLP as the independent auditors of the Company for ...
(Date:12/8/2016)... Board of Directors of the Pittsburgh Life Sciences ... only pure life sciences investment firm, today announced a ... developed by the Nominating and Governance Committee over the ... Jordan is selected to serve as President and ... who is elected to the position of Executive Chairman ...
(Date:12/8/2016)... Dec. 8, 2016  OncoSec Medical Incorporated ("OncoSec") ... DNA-based intratumoral cancer immunotherapies, today announced financial results ... "We are delivering on our commitment to ... ImmunoPulse® IL-12. We are pleased with the early ... trial, and we are focused on advancing our ...
Breaking Biology Technology:
Cached News: